



The World Health Organization Immunization Safety Priority Project

> Dr. Philippe Duclos Department of Vaccines and Biologicals World Health Organization 27th National Immunization Conference


17-20 March, 2003



Immunization Safety


"Ensuring and monitoring the safety of all aspects of immunization, including vaccine quality, storage and handling, vaccine administration and the disposal of sharps"





Proportion of New Hepatitis B Infections Attributable to Unsafe Injections, 2000

World: 35%, N= 22.5 million



Global Burden of Disease, 2000



WHO's Immunization Safety Priority Project: a Growing Partnership to Support Countries (Capacity Building)

Target:

Strengthen countries' capacity to ensure the safety of immunizations through country support to improve all programme components relevant to immunization safety

Strategy: Bring an overall culture of safety to allow for the: prevention; early detection; quick response to adverse events



Immunization Safety

1. Ensuring safety of vaccines

Use only vaccines of demonstrated quality, safety and efficacy

Strengthen National Regulatory Authorities


2. Securing safety of injections
One syringe, one needle (auto-disable syringes)
No recapping



3. Controlling safety of disposal



Past and Projected Distribution of Auto-Disable Syringes





Vaccine Safety Issues WHO perspective

Global issues with some regional differences

Implicate active ingredients or non specific substances and diseases of unknown etiology

"Amalgamation"

Potential of signal generation and systematic search to identify spurious associations and generate false hypothesis

Can generate huge amount of work and undue fear
 Need for quick hypothesis testing and international collaboration

Science compounded by legal issues

 Global supply of quality vaccines and global perspective
 Misperception that vaccines from developing countries and WHO standards sub-optimal



Examples of Programmatic Errors and Other Incidents Wrongly Attributed to the Vaccine

- Egypt: 3 deaths labelled post DPT encephalopathy due to methanol impregnated compresses, 1999
 India: outbreak of acute renal failure with neurological involvement actually due to other paramyxovirus (Nipah-Hendra type), 1998-2001
- Algeria: 7 infants died following measles vaccination.
 Use of selenium vials instead of proper diluent, 2001
- Zimbabwe: 1 infant died after measles vaccination. Review indicates toxic shock and not anaphylaxis, 2001
- Guinea: 2 adults died after yellow-fever vaccination. Investigation points to contamination of vial, 2002









Mechanisms to Respond to Safety Concerns: WHO's Support

- Technical documents (multiple languages)
 Technical assistance for investigation of serious AEFI
- Assistance with implementation or strengthening of AEFI surveillance
 Strengthening of National Regulatory Authority functions (NRA assessments)
 Training for AEFI monitoring and management (including dealing with media) - Global Training Network
 Brighton Collaboration



National Regulatory Assessments Conducted (October1998- June 2002) and experts available as of June 2002

TP-

Country status of NRA assessment

Conducted

Not yet conducted

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

0 7

Global Advisory Committee on Vaccine Safety

- To respond promptly, efficiently, independently and with scientific rigor to vaccine safety issues of global importance
- Review of latest knowledge in collaboration with all parties involved
- **Betermination of causal relationships**
- **#** Multidisciplinary, global, and under strict conflict of interest and confidentiality rules
- Ad hoc specialists teams and mandate to commission research

Best judgement in front of uncertain



Global Advisory Committee on Vaccine Safety (GACVS) : Examples of Issues 2001-2002 **Macrophagic myofasciitis H**Immunization and autoimmune diseases Safety of thiomersal **Muptiple sclerosis and hepatitis B vaccination** Leukemia following hepatitis vaccination Yellow fever vaccine-related deaths **Child survival following immunization** MMR and autism **Bell's Palsy following intranasal vaccination**

Occurrence of Bell's Palsy following Vaccination with a New Intranasal Vaccine

Results from 2 epidemiological studies indicate a significant increased risk of Bell's Palsy following intranasal vaccination with new inactivated influenza vaccine in a virosomal formulation with E. coli-derived LT adjuvant


- Manufacturer stopped distribution in May 2002
- **Review by the GACVS, June 2002 :**

Any novel vaccine for nasal administration would need to be tested on a sufficiently large number of subjects prior to licensing and submitted to active postmarketing surveillance studies

Follow-up period in the context of clinical trials should be routinely extended to 3 months for intranasal vaccines



Global Advisory Committee on Vaccine Safety: Current Communications



Global Advisory Committee on Vaccine Safety : Expanding Communications

- **February 26th partners meeting**
- Supported key role of GACVS and expanding communications around GACVS
- **Encouraged links between "qualified" sites**
 - Shared responsibility network could undermine impact and independence of GACVS and WHO
- **H**Important considerations
 - Communication about facts not advocacy
 - All safety facts good or bad!
 - **Focus on internet**



Conclusion

#Broad spectrum of immunization and vaccine safety issues **#Different priorities in different countries #Limited resources %**Need for global collaboration **#Importance of communications and** perceptions **%**Needs more attention

